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PTreating Pain in Preterm Infants: Moving from Opioids
to Acetaminophenreterm infants have many painful moments during
their stay in the neonatal nursery.1 Since the late
1980s, pediatricians and neonatologists have become
aware that not treating pain in these infants was not only
inhumane but also was associated with negative short- andSee related article, p long-term outcomes. Therefore, both non-
pharmacologic and pharmacologic inter-The authors declare no conflicts of interest.
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http://dx.doi.org/10.1016/j.jpeds.2015.09.061ventions were introduced in the care of the preterm infant
during the last 3 decades. The most commonly used drugs
to treat pain in these vulnerable infants have been, and still
are, opioids such as morphine and fentanyl. However, their
use is linked with well-known short-term adverse events
such as low blood pressure and respiratory depression.
Furthermore, depending on the duration of treatment and
the opioid used, tolerance will appear and result in an
increased opioid dose to assure continued pain relief. As a
consequence, iatrogenic opioid abstinence syndrome may
occur after discontinuation of the opioid treatment, resulting
in additional discomfort for these preterm infants with a sub-
sequent increase in the duration of their hospital stay.
In adult medicine, the use of intravenous acetaminophen
results in a so called “opioid sparing” effect but it is unclear
if this also results in less opioid-related side effects.2 The
same might hold true for the use of acetaminophen in neo-
nates and infants. Recently it was shown that the use of intra-
venous acetaminophen resulted in significantly lessmorphine
use in neonates and infants undergoing major noncardiac
surgery during the first 48 hours after surgery: 121 mg/kg vs
357 mg/kg.3 Despite this 3-fold decrease in morphine use in
the paracetamol group, no difference in adverse events was
seen.3 However, without having the assurance that adding
intravenous acetaminophen to opioids will result in less
opioid-related adverse event, neonatologists have started us-
ing intravenous acetaminophen in both term and preterm in-
fants. Thus, the article by H€arm€a et al4 in this issue of The
Journal is extremely timely and might help in the important
discussion on the question whether the use of intravenous
acetaminophen in preterm infants is already justified based
on our current knowledge. The authors found that the need
for morphine decreased significantly in preterm infants of
less than 32 weeks after the introduction of acetaminophen.
However, to reach a 2-fold reduction inmorphine use, almost
17 doses of acetaminophen per patient were needed. More-
over, there were no differences in adverse events detected be-
tween the 2 groups. Based on the current available literature in
adults, term, and preterm infants, it seems that indeed the use
of intravenous acetaminophen will reduce the amount of
morphine used in different clinical situations. However, the
question remains if acetaminophen used to decrease
morphine also improves the overall safety for the patients.Lessons Learned
Treating pain in preterm infants needs to be based on the
right indication and the use of a validated pain assessment
tool in combination with an algorithm that clearly delineatesthe necessary responses of the caregivers if
abnormal pain scores are detected. Withoutpain assessment and a treatment protocol, each preterm in-
fant treated for pain will be essentially enrolled in an uncon-
trolled and unapproved clinical trial that will not result in any
useful data.
If non-pharmacologic treatment of pain is not sufficient, a
decision to use a drug in these preterm infants should be
made. Most medications administered to preterm infants
lack information to support their efficacy and safety and, as
a consequence, around 90% of drugs given to preterm infants
have not been approved by the Food and Drug Administra-
tion. Despite this dreadful situation, there is an imperative
to treat pain in these fragile patients. Therefore, the choice
of which drug to use is often based on a variety of factors,
such as the clinical impression of the drug-prescribing
neonatologist about the severity of the pain, studies in older
infants, or any pilot data in preterm infants. After the most
appropriate drug has been selected, the next step will be to
determine the dosing regimen for that specific drug.
Now it gets very dicey as illustrated by the fact that despite
the use of opioids for over 25 years in preterm infants, only
recently dosing guidelines for preterm infants were estab-
lished that were appropriately validated.5 Until then there
has been a large variability in clinical practice resulting in
an almost 100-fold variation in dosing regimens. However,
for the use of intravenous acetaminophen, the situation is
better. There is already a lot of information on the pharma-
cokinetics of acetaminophen in preterm infants with gesta-
tional age more than 28 weeks.6 Very recently, more
information has become available for infants with gestational
ages less than 28 weeks.7 In this respect, many lessons have
been learned from our earlier experience with morphine.
Less is More?
It seems that we have better information for dosing acet-
aminophen in our youngest patients but what about safety?
It is clear that we need to design trials with sufficient power
to determine if the benefits of using a drug exceed the risks.81
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol.-, No.-In addition to short-term outcome, it will be necessary to
conduct long-term follow-up to assure that short-term pos-
itive findings do not turn bad in the long run. To be more
specific, there are very recent reports on the link between
acetaminophen use during pregnancy or in early neonatal
life and neurocognitive impairment, including attention-
deficit/hyperactivity disorder symptoms at ages 7 and
11 years, or autism spectrum disorder.9-11
Besides possibilities of short-term toxicity, there are also
epidemiologic studies that suggest a link between paraceta-
mol exposure in early infancy and the risk of asthma or other
atopy-related diseases, similar to the link between fetal/
maternal exposure and atopy in early infancy.12 There is no
causality yet, but as neonatologists we need to realize that
we treat preterm infants with medications like acetamino-
phen during vulnerable periods of development. These expo-
sures are avoided if the infant is still in utero but as soon as
the infant is born, concerns about exposure seem to decrease
or even disappear.
In summary, there is no doubt that preterm infants with
pain deserve adequate pain management. If non-
pharmacologic interventions are not sufficiently effective,
the use of medications will be necessary. At such moment,
whatever drug is chosen, it will have insufficient information
on mode of action, the pharmacokinetics, short- and long-
term safety, and ease of administration. Besides initiation,
protocols for subsequent weaning are also of utmost impor-
tance. There is an imperative to design and conduct trials
with sufficient power to determine if the drug of choice has
more benefits than risks for preterm infants. In general, it
is better to use only 1 drug for a certain indication compared
with a combination of drugs because the risks of drug–drug
interaction will increase with every drug added. Neonates are
the last therapeutic orphans but all stakeholders (regulators,
industry, academia, parents, etc.) are working to improve
that situation. Therefore, there is a huge opportunity at this
moment to improve drug treatments of infants. One of the
initiatives that has just been launched is the International
Neonatal Consortium, an initiative led by the Critical Path
Institute.13 n
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